ABT · Abbott Laboratories
$103.70
+1.16% last session
End-of-day data · close of 2026-10-23
Market cap
$179B
Enterprise value
$207B
Trailing P/E
38.6
Forward P/E
17.4
Dividend yield
2.0%
Beta
0.58
Avg volume
9M
Employees
122K
Daily Change %
1.16%
5 Days Change
-2.27%
10 Days Change
0.52%
30 Days Change
-0.34%
60 Days Change
-11.60%
Month to Day Change
6.67%
Year to Day Change
-16.15%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ABT
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-23
Latest call per bank · past 12 months
Wells Fargo
Overweight$120
+15.7% vs priceCitigroup
Buy$122
+17.6% vs priceRBC Capital
Outperform$125
+20.5% vs priceJP Morgan
Overweight$118
+13.8% vs priceBarclays
Overweight$120
+15.7% vs priceUBS
Buy$125
+20.5% vs priceGoldman Sachs
Buy$113
+9.0% vs priceBank of America
Buy$120
+15.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-23 | Wells Fargo | Maintains | Overweight | $119 → $120 |
| 2026-10-22 | Citigroup | Maintains | Buy | $125 → $122 |
| 2026-10-22 | RBC Capital | Maintains | Outperform | $130 → $125 |
| 2026-10-22 | Wells Fargo | Maintains | Overweight | $112 → $119 |
| 2026-10-22 | JP Morgan | Maintains | Overweight | $120 → $118 |
| 2026-10-22 | TD Cowen | Maintains | Buy | $135 → $118 |
| 2026-10-22 | Baird | Maintains | Outperform | $121 → $123 |
| 2026-10-22 | BTIG | Maintains | Buy | $134 → $125 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 55 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 0.9% below the 50-day MA ($104.61).
- bullish: Price vs 200-day MA: Trading 2.8% above the 200-day MA ($100.92).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.51) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($81.47) and high ($127.42).
ABT Price Chart
Loading chart for ABT…
Fundamentals
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
More in Medical Devices
MDT
Medtronic plc.
$122B 3.1% YTD
SYK
Stryker Corporation
$118B -11.9% YTD
BSX
Boston Scientific Corporation
$66B -51.7% YTD
EW
Edwards Lifesciences Corporatio
$51B 5.7% YTD
GEHC
GE HealthCare Technologies Inc.
$33B -12.8% YTD
DXCM
DexCom, Inc.
$29B 18.0% YTD
PHG
Koninklijke Philips N.V. NY Reg
$26B 3.3% YTD
STE
STERIS plc (Ireland)
$23B -7.6% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.